Recce Pharmaceuticals: Makes quarterly progress on R327
- Recce Pharmaceuticals (RCE) progresses clinical trials of its R327 drug candidate during the June quarter
- One of the company’s standout moments for the period has been successfully dosing two cohorts with higher doses in its phase one intravenous clinical trial
- Over the three-month period, Recce recorded cash outflows of $4.5 million, of which $2.91 million was directed to research and development
- The company finishes the period with $11.58 million in cash and cash equivalents
- Shares are trading flat at 89 cents each at 1:00 pm AEST
